HCB 303
Alternative Names: HCB-303Latest Information Update: 25 Aug 2023
At a glance
- Originator HanchorBio
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Jun 2023 Preclinical trials in Cancer in Taiwan (Parenteral), prior to June 2023 (HanchorBio pipeline, June 2023)